atiprimod atiprimod atiprimod (inn, codenamed sk&f106615) is a substance being studied in the treatment of certain multiple myelomas and other advanced cancers. it may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. this drug is also being researched as a potential treatment for various autoimmune diseases. it was first developed by glaxosmithkline as a potential treatment for rheumatoid arthritis. the substance is also known as azaspirane, although this more properly refers to the class of chemicals to which atiprimod belongs. atiprimodclinical dataatc codenoneidentifiers iupac name 3-(8,8-dipropyl-3-azaspirodecan-3-yl)-n,n- diethylpropan-1-amine cas number123018-47-3 npubchem cid129869chemspider114962 yuniimg7d3qd743keggd03003 nchemblchembl103735 ycomptox dashboard (epa)dtxsid10153834 chemical and physical dataformulac22h44n2molar mass336.608 g·mol−13d model (jsmol)interactive image smiles n(cc)(cc)cccn2ccc1(ccc(cc1)(ccc)ccc)c2 inchi inchi=1s/c22h44n2/c1-5-10-21(11-6-2)12-14-22(15-13-21)16-19-24(20-22)18-9-17-23(7-3)8-4/h5-20h2,1-4h3 ykey:serhttslbvgrby-uhfffaoysa-n y ny (what is this?) (verify) this compound has also been shown to kill mantle cell lymphoma cells in vitro. mechanism of action atiprimod has been shown to inhibit angiogenesis (growth of blood vessels) in a blood vessel model using chicken eggs. it is thought to inhibit the secretion of vascular endothelial growth factor (vegf), a growth factor that promotes angiogenesis. chemistry atiprimod is an amphiphilic compound and a cation at neutral ph. synthesis atiprimod synthesis: anormed inc. dagger, r. e.; grady, c. w.; 1999, u.s. patent 5,952,365.